First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients

Abstract Background NS5A and NS5B proteins of hepatitis C virus (HCV) are the main targets of compounds that directly inhibit HCV infections. However, the emergence of resistance-associated substitutions (RASs) may cause substantial reductions in susceptibility to inhibitors. Methods Viral load and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zahra Hasanshahi, Ava Hashempour, Farzane Ghasabi, Javad Moayedi, Zahra Musavi, Behzad Dehghani, Heidar Sharafi, Hassan Joulaei
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
HCV
Acceso en línea:https://doaj.org/article/26e1999e836e4135ad9b6588156afa79
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!